February 14, 2025 – IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented Phase 1 data on its allogeneic gamma ...
February 14, 2025 - IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, yesterday presented ...
IN8bio (INAB) presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy, ...
GlobalData on MSN17h
TC BioPharm completes dosing in Cohort A of Phase IIb trial for AMLThe trial was designed to evaluate the therapy’s efficacy and safety in treating AML, as well as myelodysplastic syndromes.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
NEW YORK - IN8bio, Inc. (Nasdaq: INAB), a biopharmaceutical company specializing in gamma-delta T cell therapies with a current market capitalization of $23.42 million, has announced encouraging Phase ...
OU’s Phi Gamma Delta chapter, commonly known as FIJI, has come to a new educational agreement with the university following multiple alcohol and hazing strikes from last year.
As the clock struck 1 p.m. on Thursday, the rhythm of grocery carts resonated throughout the lobby of Wesley House as ...
Prime Video’s ‘Sweethearts’ follows six high school couples as they navigate the key milestones of their senior year. The series captures the various ways these young individuals experience and manage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback